Alteration of erythrocyte membrane Na, K-ATPase in children with borderline or essential hypertension.
The aim of this study was to evaluate the substrate (ATP) kinetics of erythrocyte membrane Na, K-ATPase in children with borderline or essential hypertension. Although the activity of Na, K-ATPase in the presence of in vivo concentrations of ATP was not significantly altered, kinetic studies showed an obvious inhibition of enzyme activity in the erythrocyte membrane of children with borderline or essential hypertension. Hanes plot analysis revealed a decrease of V(max) from 7.19 in erythrocytes from control subjects to 4.93 and 3.33 in those from children with borderline or essential hypertension, respectively. A mean value of the K(m) decreased from 0.10 in the control to 0.08 and 0.02 in children with borderline or essential hypertension, respectively. The energy status of erythrocytes, estimated by ATP, ADP and AMP levels, ATP/ADP ratio, and adenylate energy charge (AEC) was not significantly changed in the cells from hypertensive children. The use of a free radical-generating system (FeSO4/ascorbate) in vitro significantly reduced enzyme activity in the control erythrocytes while in those from hypertensive children it was abolished completely. The level of lipid peroxides was considerably higher (+ 37 per cent) in the plasma, while that of reduced glutathione was significantly lower both in the erythrocytes and the plasma of children with essential hypertension than in healthy children. These results indicate significant alterations of the antioxidant status which could be the cause of the inhibited Na, K-ATPase activity in erythrocyte membranes from hypertensive children.
Stojadinovic
N D
ND
Institute of Physiology, Faculty of Medicine, Clinical Hospital Centre Kragujevac, University of Kragujevac, Yugoslavia.
Petronijević
M R
MR
Pavićević
M H
MH
Mrsulja
B B
BB
Kostić
M M
MM
D000244:Adenosine Diphosphate / Q000378:metabolism; D000249:Adenosine Monophosphate / Q000378:metabolism; D000255:Adenosine Triphosphate / Q000378:metabolism / Q000494:pharmacology; D000293:Adolescent; D002474:Cell-Free System; D002648:Child; D004910:Erythrocyte Membrane / Q000187:drug effects / Q000201:enzymology* / Q000473:pathology; D005260:Female; D005609:Free Radicals / Q000378:metabolism / Q000494:pharmacology; D005978:Glutathione / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000201:enzymology* / Q000473:pathology; D007700:Kinetics; D008297:Male; D000254:Sodium-Potassium-Exchanging ATPase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D013379:Substrate Specificity; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism
D005609:Free Radicals; D017392:Thiobarbituric Acid Reactive Substances; D000249:Adenosine Monophosphate; D000244:Adenosine Diphosphate; D000255:Adenosine Triphosphate; D000254:Sodium-Potassium-Exchanging ATPase; D005978:Glutathione